Photo of Glen T. Schumock

Glen T. Schumock


Dean, College of Pharmacy
Professor, College of Pharmacy - Pharmacy Systems, Outcomes and Policy

Related Sites:

Teaching and Supervision

Ph.D. Thesis Research (PSOP 599), 8/23/2021 – 12/3/2021
Ph.D. Thesis Research (PSOP 599), 1/11/2021 – 4/30/2021
Res in Pharm Syst Outcomes Pol (PSOP 380), 8/28/2017 – 12/8/2017
Pharm Services & Reimbursement (PHAR 346), 8/28/2017 – 12/8/2017
Pharm Services & Reimbursement (PHAR 346), 8/28/2017 – 12/8/2017
Ph.D. Thesis Research (PSOP 599), 8/28/2017 – 12/8/2017
Seminar Pharm Syst Outcome Pol (PSOP 595), 1/9/2017 – 4/28/2017
Ph.D. Thesis Research (PSOP 599), 1/9/2017 – 4/28/2017
Res in Pharm Syst Outcomes Pol (PSOP 380), 1/9/2017 – 4/28/2017

Selected Grants

Risk of Venous Thromboembolism Following Diagnosis and Treatment of Multiple Myeloma : differences by race, National Institutes of Health (National Heart, Lung, and Blood Institute)., 1/1/2018 - 12/31/2019, Obligated Amount: $438969; Anticipated Amount: $438969

Second Generation Antipsychotics on Diabetes Outcomes in Major Depression, Funded by National Institutes of Mental Health., 8/8/2017 - 8/7/2018, Obligated Amount: $28044; No Anticipated Amount Set

Medication Safety Systems in the Community: the Role of Pharmacists White Paper, Gordon & Betty Moore Foundation., 6/1/2017 - 12/31/2017, Obligated Amount: $77130; Anticipated Amount: $77130

Institute for Clinical and Economic Review Modeling Studies, Institute for Clinical and Economic Review., 3/16/2017 - 3/15/2018, Obligated Amount: $125000; No Anticipated Amount Set

Institute for Clinical and Economic Review Consulting Agreement, Institute for Clinical Research Inc., 3/16/2017 - 12/31/2020, Obligated Amount: $500000; Anticipated Amount: $500000

Anticoagulation Self-Monitoring In Minority Patients, National Institutes of Health (National Heart, Lung, and Blood Institute)., 2/1/2016 - 1/31/2018, Obligated Amount: $132095; Anticipated Amount: $132095

Sentinel Initiative, Food and Drug Administration., 1/1/2015 - 12/31/2020, No Obligated Amount Set; No Anticipated Amount Set

UIC Center of Excellence for Comparative Effectiveness Research Educational Program, PhRMA Fdn., 1/1/2015 - 12/31/2016, Obligated Amount: $250032; Anticipated Amount: $250032

2015 Center of Excellence for Comparative Effectiveness Research (CER) Education., Pharmaceutical Research and Manufacturers Association (PhRMA) Foundation.., 1/1/2015 - 12/31/2017, Obligated Amount: $250000; No Anticipated Amount Set

Selected Publications

Moran, KM, Calip, GS, Lee, TA, Koronkowski, MJ, Lau, DT, Schumock, GT. (2021). Risk of fall-related injury and all-cause hospitalization of select concomitant central nervous system medication prescribing in older adult persistent opioid users: A case-time-control analysis. Pharmacotherapy, 41, (9), 733-742. doi:10.1002/phar.2612.

Tichy, EM, Hoffman, JM, Suda, KJ, Rim, MH, Tadrous, M, Cuellar, S, Clark, JS, Wiest, MD, Matusiak, LM, Schumock, GT. (2021). National trends in prescription drug expenditures and projections for 2021. American Journal of Health-System Pharmacy, 78, (14), 1294-1308. doi:10.1093/ajhp/zxab160.

Patel, H, DiDomenico, RJ, Suda, KJ, Schumock, GT, Calip, GS, Lee, TA. (2020). Risk of cardiac events with azithromycin—A prediction model. PLoS ONE, 15, (10 October). doi:10.1371/journal.pone.0240379.

Patel, H, Calip, GS, DiDomenico, RJ, Schumock, GT, Suda, KJ, Lee, TA. (2020). Comparison of Cardiac Events Associated With Azithromycin vs Amoxicillin. JAMA network open, 3, (9), e2016864. doi:10.1001/jamanetworkopen.2020.16864.

Tichy, EM, Schumock, GT, Hoffman, JM, Suda, KJ, Rim, MH, Tadrous, M, Wiest, MD, Matusiak, LM, Clark, JS, Cuellar, S, Stubbings, JA, Vermeulen, LC, Hunkler, RJ. (2020). National trends in prescription drug expenditures and projections for 2020. American Journal of Health-System Pharmacy, 77, (15), 1213-1230. doi:10.1093/ajhp/zxaa116.

Sharma, D, Schumock, GT, Saffore, CD, Albert Edwards, S, Walton, SM. (2020). Estimating the Impact of Food and Drug Administration’s Unapproved Drug Initiative on Drug Prices and Sales. Therapeutic Innovation and Regulatory Science, 54, (2), 424-430. doi:10.1007/s43441-019-00072-8.

Patel, H, Calip, GS, DiDomenico, RJ, Schumock, GT, Suda, KJ, Lee, TA. (2020). Prevalence of Cardiac Risk Factors in Patients Prescribed Azithromycin before and after the 2012 FDA Warning on the Risk of Potentially Fatal Heart Rhythms. Pharmacotherapy, 40, (2), 107-115. doi:10.1002/phar.2355.

Harrington, RL, Qato, DM, Antoon, JW, Caskey, RN, Schumock, GT, Lee, TA. (2020). Impact of multimorbidity subgroups on the health care use of early pediatric cancer survivors. Cancer, 126, (3), 649-658. doi:10.1002/cncr.32201.

Gor, D, Lee, TA, Schumock, GT, Walton, SM, Gerber, BS, Nutescu, EA, Touchette, DR. (2020). Adherence and persistence with DPP-4 inhibitors versus pioglitazone in type 2 diabetes patients with chronic kidney disease: A retrospective claims database analysis. Journal of Managed Care and Specialty Pharmacy, 26, (1), 67-75P. doi:10.18553/jmcp.2020.26.1.67.

Education

Degrees:
Bachelors of Pharmacy, Washington State University, United States, 1987
Doctor of Pharmacy, School of Pharmacy, University of Washington, United States, 1989
Masters of Business Administration, University of Illinois at Chicago, United States, 1994
Doctor of Philosophy in Public Health Sciences - Pharmacoepidemiology, University of Illinois at Chicago, United States, 2012

Selected Presentations

Harrington, RL, Qato, DM, Antoon, JW, Caskey, RN, Schumock, GT, Lee, TA. (2019 June 01). Multimorbidity and healthcare utilization among early survivors of pediatric cancer. doi:10.1002/pbc.27655.
Adimadhyam, Sruthi, Lee, Todd A, Calip, Gregory S, Marsh, Daphne E Smith, Layden, Brian T, Schumock, Glen T. (2018 August 01). Risk of amputations associated with SGLT2 inhibitors: A propensity-matched cohort study.
Adimadhyam, Sruthi, Lee, Todd A, Calip, Gregory S, Marsh, Daphne E Smith, Layden, Brian T, Schumock, Glen T. (2018 August 01). SGLT2 inhibitors and mycotic infections: A prescription sequence symmetry analysis.